 BeiGene Ltd NASDAQ: BGNE has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a first-line treatment of recurrent or metastatic nasopharyngeal cancer, a rare type of head and neck cancer. The trial demonstrated a statistically significant improvement primary endpoint in progression-free survival compared to chemotherapy alone at the interim analysis, as recommended by an independent data monitoring committee. 